Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
238lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Learning paths
Pick a track — progress rings update as you complete lessons.
12 lessons
6mResearchBeginner
Macupatide Beginner's Guide: Lilly's LY3532226 Pipeline Peptide
Macupatide is the Lilly code name beside eloralintide that most people skip. This beginner guide explains what it is — and what not to invent about dosing yet.
7mResearchAdvanced
Macupatide and Eloralintide: Lilly's Next Amylin Combination Angle
Eloralintide is only half the Lilly amylin headline. Macupatide shows up in the same ClinicalTrials.gov cluster. Here's the combo literacy guide.
8mResearchAdvanced
Eloralintide vs Petrelintide: Lilly vs Roche Amylin Agonists
Two weekly amylin programs, two sponsors, two data shapes. Here's a clear eloralintide vs petrelintide comparison for people following the next obesity wave.
9mPeptidesIntermediate
Eloralintide Beginner's Guide: What LY3841136 Is and Why Amylin Matters
Eloralintide is Lilly's once-weekly selective amylin receptor agonist. If you follow GLP-1s, CagriSema, or retatrutide, this is the next pathway to understand — satiety biology, trial doses, and what the early data actually show.
8mProtocolsIntermediate
Eloralintide Dosing Guide: Phase 2 Doses, Titration, and Weekly Protocol
Searching for eloralintide dosage? Here is the clean map of Phase 2 once-weekly doses, titration arms, and weight-loss results — framed as clinical education, not a DIY protocol.
8mResearchAdvanced
Eloralintide vs Cagrilintide: Amylin Agonists Compared
Both hit amylin biology. One is Lilly's Phase 3 monotherapy / combo candidate. The other is the amylin half of CagriSema. Here's a clear comparison for people following the next wave of obesity peptides.
8mProtocolsIntermediate
Eloralintide + GLP-1 / Tirzepatide: The Amylin Add-On Stack Explained
Amylin + incretin is the stacking thesis behind CagriSema — and now eloralintide. Here's the clinical logic for combining pathways, without turning investigational drugs into DIY stacks.
8mResearchAdvanced
Eloralintide Weight Loss Results: Phase 2 Data and What to Watch in Phase 3
Phase 2 put eloralintide on the board with roughly 9–20% mean weight loss at 48 weeks. Here's the results breakdown — and the troubleshooting mindset for plateaus on any amylin or GLP-1 protocol.
8mProtocolsIntermediate
Orforglipron Dosing Guide: Oral GLP-1 Titration to 6, 12, and 36 mg
Orforglipron is Lilly's once-daily oral small-molecule GLP-1. Here's the titration ladder searchers want — 1 mg start, step-ups every four weeks, and Phase 3 maintenance doses.
10mResearchAdvanced
Retatrutide's July 23 Phase 3 Readout Keeps Raising the Ceiling
Retatrutide just posted two more strong phase 3 wins. The new numbers matter, but the bigger story is how phase 1, phase 2, and phase 3 now line up into one very clear dose-response story.
8mResearchAdvanced
Retatrutide TRIUMPH-1 Phase 3 Results: How to Track the 28.3% Weight Loss Data
The new TRIUMPH-1 readout gives retatrutide users a clearer dose-response map: 4 mg, 9 mg, and 12 mg all worked, but the tolerability tradeoffs matter.
9mResearchAdvanced
Retatrutide Phase 3 Results: 28.7% Weight Loss Sets New Standard
New Phase 3 data shows Retatrutide nearly doubled the weight loss results of current GLP-1 drugs without hitting a plateau.
Also available at /blog for legacy links.